<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745237</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008224</org_study_id>
    <secondary_id>DCMRC-8224a</secondary_id>
    <nct_id>NCT01745237</nct_id>
  </id_info>
  <brief_title>Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis</brief_title>
  <official_title>Detection and Prognostic Significance of Myocardial Damage Visualized by Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine the ability of cardiac magnetic
      resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were
      to undergo CMR in addition to routine clinical evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with sarcoidosis, cardiac death is a leading cause of mortality which may
      represent unrecognized cardiac involvement. Cardiovascular magnetic resonance (CMR) can
      detect cardiac involvement including minute amounts of myocardial damage. Therefore, the
      objective of this study was to determine the usefulness of CMR and compare it with standard
      clinical evaluation for cardiac involvement. Patients with documented extracardiac
      sarcoidosis or clinically suspected cardiac sarcoidosis will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2002</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>cardiac mortality</measure>
    <time_frame>&gt; 1year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>arrhythmic death</measure>
    <time_frame>&gt; 1year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary mortality</measure>
    <time_frame>&gt; 1year</time_frame>
    <description>only in subset of patients with pulmonary sarcoidosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>&gt; 1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arrhythmic events</measure>
    <time_frame>&gt; 1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Transplant</measure>
    <time_frame>&gt; 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Transplant</measure>
    <time_frame>&gt; 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPM placement/high grade AV block</measure>
    <time_frame>&gt; 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sarcoidosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with biopsy proven sarcoidosis or suspected cardiac sarcoidosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven sarcoidosis

          -  Suspected cardiac sarcoidosis

        Exclusion Criteria:

          -  Contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond J Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han W Kim, MD</last_name>
    <phone>919-668-3539</phone>
    <email>kim00050@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond J. Kim, MD</last_name>
    <phone>919-668-3539</phone>
    <email>kim00049@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han W Kim, MD</last_name>
      <phone>919-668-3539</phone>
      <email>kim00050@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raymond J Kim, MD</last_name>
      <phone>919-668-3539</phone>
      <email>kim00049@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond J Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2.</citation>
    <PMID>19884472</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>Cardiac Magnetic Resonance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

